Drug Development Pipeline

The drug development pipeline extends the discovery process described above through preclinical safety evaluation, regulatory submission, and clinical...

The drug development pipeline extends the discovery process described above through preclinical safety evaluation, regulatory submission, and clinical testing to eventual market approval. Following selection of a preclinical candidate, comprehensive preclinical pharmacology and toxicology studies generate the safety and efficacy package required for an Investigational New Drug application; successful review permits first-in-human Phase I trials assessing safety and tolerability, followed by Phase II trials assessing preliminary efficacy and Phase III trials providing confirmatory evidence against existing therapy, culminating in a New Drug Application seeking marketing authorisation. The extended duration, cost, and high attrition rate characteristic of this pipeline — historically requiring upwards of a decade and the equivalent of several hundred million to over a billion dollars per approved medicine — underscore why the rigour of the medicinal chemistry work performed at the discovery stage, the subject of this text, is so consequential to the eventual success or failure of the overall development programme.

Insert appropriate diagram/illustration here

The illustration should depict the drug development pipeline as a linear flow diagram, beginning with target identification and validation, proceeding through hit identification, lead identification, and lead optimization, and continuing through preclinical safety evaluation, IND submission, and Phase I–III clinical trials to final regulatory approval, with an indicative timeline and approximate attrition rate labelled at each stage.